Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Tolebrutinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sanofi's Cenrifki For Secondary Progressive Ms Recommended
    Sanofi's Cenrifki For Secondary Progressive Ms Recommended

    24 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/24/3280641/0/en/press-release-sanofi-s-cenrifki-tolebrutinib-recommended-for-eu-approval-by-the-chmp-to-treat-secondary-progressive-multiple-sclerosis-without-relapses.html

    GLOBENEWSWIRE
    24 Apr 2026
    Share Share
    FDA Shares CRL For Sanofi MS Drug Mere Weeks After Rebuff
    FDA Shares CRL For Sanofi MS Drug Mere Weeks After Rebuff

    06 Jan 2026

    // FIERCE PHARMA

    https://www.fiercebiotech.com/biotech/fda-cites-severe-liver-injury-risk-unclear-benefit-behind-sanofis-ms-drug-rejection

    FIERCE PHARMA
    06 Jan 2026
    Share Share
    Tiziana Reports Annual Safety Data For Intranasal Foralumab
    Tiziana Reports Annual Safety Data For Intranasal Foralumab

    29 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/29/3210895/0/en/Tiziana-Files-Annual-Safety-Report-for-Intranasal-Foralumab-with-FDA.html

    GLOBENEWSWIRE
    29 Dec 2025
    Share Share
    Sanofi Provides Update on Tolebrutinib Regulatory Submission
    Sanofi Provides Update on Tolebrutinib Regulatory Submission

    24 Dec 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-12-24-06-00-00-3210238

    PRESS RELEASE
    24 Dec 2025
    Share Share
    Sanofi Updates Tolebrutinib for Primary Progressive MS
    Sanofi Updates Tolebrutinib for Primary Progressive MS

    15 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/15/3205094/0/en/Press-Release-Sanofi-provides-update-on-tolebrutinib-in-primary-progressive-multiple-sclerosis.html

    GLOBENEWSWIRE
    15 Dec 2025
    Share Share
    Update on the US Regulatory Review of Tolebrutinib in MS
    Update on the US Regulatory Review of Tolebrutinib in MS

    22 Sep 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-09-22-05-00-00-3153624

    PRESS RELEASE
    22 Sep 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.